Research library / Other

AA Multiple randomized trials or meta-analyses, consistent results. How we grade →RCT · 27,564 people with atherosclerotic disease on statins

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

M Sabatine, R Giugliano, A Keech, N Honarpour, S Wiviott, S Murphy et al. New England Journal of Medicine. 2017.

Published Sources checked 1 sourceEverstack research teamHow we work

In plain language
FOURIER: evolocumab lowered LDL cholesterol by 59% and the main composite of heart events by 15% (HR 0.85) over a median 2.2 years.
Limits
People with established heart disease, short follow-up. Funded by Amgen, the drug's maker.
Which of our grades it feeds
Source
doi.org/10.1056/NEJMoa1615664 · PubMed 28304224

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.